Close Menu

NEW YORK (GenomeWeb) – HER3 expression levels can distinguish colorectal cancer patients with wild-type RAS tumors who will respond to anti-EGFR therapy, according to a new study.

While RAS testing can identify colorectal cancer patients who won't respond to treatment with an anti-EGFR therapy like panitumumab, it doesn't necessarily identify patients who will benefit from such treatment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.